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D95945 The Vasodilator Effscts of Cyclic GMP Do NotExplainthe Venosslsctivityof NitricOxideDonora
In Humans
I.D. Cox, J. Collier, R.J. McAllister. St George’s Hospital, London, UK
A reduetlon of the arterial effects of the endogenous dilator, nitric oxide (NO),
has been implicated in the development of hypertension and atheroma in
humana, and these effects might be reversad by NO-replacement therapy.
Currently available NO-donors such as glycetyl trinitrate (GTN) are venose-
Iective, and this Iimitstheir usefulness in targeting the arterial circulation. The
second messengar for endogenous and exogenous NO is cyclic GMP which
,is synthesisad in the smooth muscle by guanylate cyclase. The aim of this
study was to determine whether the venoselectivity of GTN was similar to
cyclic GMP. Dose-response curves to GTN or 8-bromocyclic GMP (a stable
cyclic GMP analogue) were constructed in preconstructeddorsal hand veins
(0.5-8 pmol/min and 50-200 nmol/min, respectively; n =6) and in the fore-
arm resistance bed (0.25-1 nmol/min and 0.5-2 wmol/min, respectively; n =
6) of healthy volunteers. GTN dilated veins at doses 1000-fold amaller than
dilated the forearm vascular bed. In contrast, 6-bromoeyclic GMP dilated
veins at dosea that were 10-fold smaller than those that dilated the forearm
resistance bed (Figure).
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Arteriovenousprofilesof GTN and 8-bromoeyclicGMP
Allowing for a 10-20 fold difference between venous and arterial blood
flow, these results indicate that cyclic GMP is not venoselective. GTN and
other NO donore might be venoselactive by stimulating greater cyclic GMP
increasea in venous than arterial smooth muscle.
D95946 Pharmacodynamica of Basic Fibrobiaat GrowthFactor: Effect of Routs of Administration on
Regional Distribution
D.F. Lszarous, M. Shou, J.A. Stiber, D. Dadhania, V. Thirumufti, E, Hedge,
E.F. Unger. Cardiology Branch, NHLBI, Bethesda, MD, USA
Our laboratory has shown that basic fibroblast growth factor (bFGF) en-
hances myocardial collateral development in a canine model of chronic
ischemia when delivered via the left atrial (LA) or intracoronary (IC) routes;
however,wehavefound intravenous (IV) bFGFineffective inthesame model.
Data on the fate and efficacy of IV bFGF are limited. We hypothesized that
first pees lung uptake might limit myocsrdial bFGF deposition after IV in-
jection, and postulated that delivety of bFGF through the distal port of a
wedged Swan Ganz (SG) catheter might circumvent this problem. We there-
fore evaluated differential regional uptake of I-125 labeled bFGF following
bolus IV,SG, LA, IC, and pericardial delivety in fourteen dogs. I-125 activity
was asaessed 15 and 150 min after injection; percent recovered bFGF was
the primary end point. Serum half life of bFGF was comparable after IC, IV
and LA delivey (50 rein); however, there were significant differences with re-
gard to pharmacodynamics. After IC administration, 3-5% of the total bFGF
dose was recovered from the heart, with the peptide immunolocalized to the
extracellular MatriX and VaSCUiar endothelium. In COntraSt, only 1.3Y0of the
injected bFGF was Ioeaiized to the heart after LA administration, and 0.5%
was recovered after IV or SG delivery. Pericardial administration resulted in
the greatest cardiac bFGF delivety; 19% of the injected dose was present
at 150 min. These data provide a rationale for the efficacy of IC, LA, and
perfcardial bFGF for myocerdial angiogenesis, and predict a lack of efficacy
after bolus IV and SG administration.
1959-471 Loop Diuretics Enhanced Secretion of ProstacWiin
in Vitro and in Patients with Heart Failure
A. Liguori, F.P.D’Armiento, A. Casini 1, M. Lecuesez, C. Napoli. 1Division of
Cardio/ogy-CCU, Pe//egrini Hospital, institute of Human Pathology
Univeraityof Naples, C/inica/ Pharmacology Unit, Florence, /ta/K 2 Divis/on
of /ntema/ Medicine, Po/ic/inico Casi/ino, Rome, Italy
Previousstudies suggest that theacutehemodynamic effeets of Ioopdiuretics
are due to a direct dilation on blood vessels, are not related to diuretic prop-
erties, but perhaps to prostaglandin secretion. Thus, we firstly investigated
whether human endothelial cells reaponded to torasemide or furosemida
with an enhanced secretion of the vasodilator prostaglandin prostacyclin
(PG12).Moreover, in patients with congestive heart failure (CHF), whose sys-
temic vascular resistance is already high, the venodilator affects of the loop
diuretics might be prolonged. Thus, we also investigated whether plasma
concentrations of PGIz after twenty-five min administration of torasemideor
frusemide in twenty-six patients with CHF (NYHA Ill) were increased. The
PG12levels were measured after extraction in ethyl acetate by RIA as levels
of 6-Keto-PGFla, a stable metabolize.Data ahowad that in primary cultured
human endothelial cells both frusemide (3 x 10-7 moil) and torasemide
(10-7 mol/1)induced PGIz secretion (865 + 55 and 1250 + 85* n~mg of
protein, respectively;”p <0.05 vs frusemide) that reached a peak after about
five minutes and remained stable for 35 min of continuous exposure of cells
to diuretics. In CHF patients, we observed a significant decrease of left ven-
tricular end diastolic pressure in both group of patients after 25 min from
the loop diuretic infusion. This effect might be due to a synergism between
decrease in plasma volume induced by diuresis and PGIPsecretion. Basal
levels of PGIPsynthesis were similar between the two groups of CHF pa-
tients. However, PGIz levels were significantly increased after25 min of both
drug infusion (p < 0.05). This increase was significantly higher in patients
treated with 10 mg of torasemide than in patients treated with 40 mg of
frusemide (155+ 35* vs 118+29 pg/ml; *p <0.05 vs frusemide).
Thus, ourdatashowed an enhanced secretion of PGIzafter both torasemide
and frusemide administration either in vitro or in CHF patients. This phe-
nomenon, which may explain in part the vaaodilatory effects of these drugs,
was more evident with torasemide and reached at lower concentrations of
the drug.
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Tiasue Factor-Activated Thromboeiaatography
S. Khurana, J.C. Mattson, E. Cohen, S. Westley, W.W. O’Neill, G.C: Timmis,
R.D. Safian. Wi//iamBeaumont Hospita/, Royal Oak, Ml, USA
Computerized thromboelastography (TEG) wasusedtostudy platelet GPllb/llla
function, characterize the consequences of the interaction between poly-
merizing fibrin and activated platelets, and establish a quantitative assay of
platelet function. The ability of platelets to augment the shear elastic modulus
of blood clots was measured using TEG under maximal activating conditions
during clot formation accelerated by recombinant human tissue factor. Under
these conditions, platelets significantly enhance clot strength eight fold. This
effect, inhibited by Cytochalasin D and c7E3 Fab, is dependent on the trws-
mission of platelet contractile force to fibrin, via GPllb/llla. The c7E3 Fab
dose-response of TF-TEG clot strength is identical to results with platelet
aggregation induced by the thrombin receptor agonist peptide (TRAP,+);
ADP-inducad aggregation is easier to inhibit.
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Results obtained with this system are reproducible (CV 4%, r 0.96). As a
clinical assay, TEG can be rapidly performed at at the bedside (results in <
30 rein), requires only 0.345 ml of unprocessed whole blood, and may offer
advantages over conventional measures of platelet function.
